These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23964940)

  • 1. Inhibition of leukocyte trafficking in inflammatory bowel disease.
    Cominelli F
    N Engl J Med; 2013 Aug; 369(8):775-6. PubMed ID: 23964940
    [No Abstract]   [Full Text] [Related]  

  • 2. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intestine selective therapy].
    Maronde U
    MMW Fortschr Med; 2015 Jul; 157(13):80. PubMed ID: 26206050
    [No Abstract]   [Full Text] [Related]  

  • 6. THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.
    Kotze PG; Damião AO; Moraes AC
    Arq Gastroenterol; 2016; 53(1):3-4. PubMed ID: 27276096
    [No Abstract]   [Full Text] [Related]  

  • 7. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinating patients with inflammatory bowel disease--primum non nocere.
    Muhammad R; Wong CL; Limdi JK
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1122-3. PubMed ID: 22554229
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs.
    Romano C; Sinagra E; Criscuoli V; Orlando A; Maisano S; Cottone M
    J Crohns Colitis; 2013 Oct; 7(9):e405-6. PubMed ID: 23764367
    [No Abstract]   [Full Text] [Related]  

  • 12. Bugs and drugs: Predicting response to therapy.
    Ananthakrishnan AN
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():27. PubMed ID: 30187562
    [No Abstract]   [Full Text] [Related]  

  • 13. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML
    World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):941-950. PubMed ID: 28169436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why does Pharmac neglect inflammatory bowel disease?
    McCombie A; Arnold M; O'Connor M; Stein R; Fulforth J; Brown B; Gearry R
    N Z Med J; 2020 Dec; 133(1527):111-115. PubMed ID: 33332333
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world evidence for vedolizumab: Understanding the landscape.
    Lawrance IC; Pulusu SSR
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
    [No Abstract]   [Full Text] [Related]  

  • 17. Vedolizumab for the treatment of ulcerative colitis.
    Rietdijk ST; D'Haens GR
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 19. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
    Luthra P; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
    Poulakos M; Machin JD; Pauly J; Grace Y
    J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.